vofatamab

BIOLOGICAL2 trials

Sponsors

Rainier Therapeutics, Fusion Pharmaceuticals Inc.

Conditions

Advanced Solid TumorBladder CarcinomaBreast CancerColorectal CancerFGFR3FGFR3 OverexpressionFGFR3 Protein OverexpressionFGFR3 Receptor

Phase 1

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

TerminatedNCT02401542

Rainier TherapeuticsLocally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases

Start: 2015-06-30End: 2019-11-01Updated: 2020-03-09

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

TerminatedNCT05363605

Fusion Pharmaceuticals Inc.Advanced Solid Tumor, Bladder Carcinoma, Breast Cancer +11

Start: 2022-04-20End: 2023-09-08Updated: 2023-12-19

Related Papers

Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2019-05-209 citations

Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2019-03-0143 citations

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

Journal of Clinical Oncology2018-05-2024 citations

Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma.

Journal of Clinical Oncology2017-05-2010 citations